Welcome to the UPF Digital Repository

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer

Show simple item record

dc.contributor.author Cremolini, Chiara
dc.contributor.author Montagut Viladot, Clara
dc.contributor.author Ronga, Philippe
dc.contributor.author Venturini, Filippo
dc.contributor.author Yamaguchi, Kensei
dc.contributor.author Stintzing, Sebastian
dc.contributor.author Sobrero, Alberto
dc.date.accessioned 2024-04-24T06:42:22Z
dc.date.available 2024-04-24T06:42:22Z
dc.date.issued 2023
dc.identifier.citation Cremolini C, Montagut C, Ronga P, Venturini F, Yamaguchi K, Stintzing S, et al. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Front Oncol. 2023 Feb 2;12:946850. DOI: 10.3389/fonc.2022.946850
dc.identifier.issn 2234-943X
dc.identifier.uri http://hdl.handle.net/10230/59876
dc.description.abstract In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on treatment with anti-EGFR-based therapy can be resistant to further anti-EGFR treatment, but evidence suggests that the anti-EGFR-resistant clones decay, thereby opening the potential for rechallenge or reintroduction in later lines of treatment. Results from recent clinical studies have shown that some patients with mCRC who are rechallenged with anti-EGFR monoclonal antibodies exhibit durable responses. While other therapies have demonstrated improved overall survival in chemorefractory mCRC over the past decade, rechallenge with anti-EGFR monoclonal antibodies in later lines of treatment represents a new option that deserves further investigation in clinical trials. In this review, we summarize the molecular rationale for rechallenge or reintroduction in patients with mCRC who have progressed on earlier-line anti-EGFR treatment and examine the current evidence for using liquid biopsy as a method for selecting rechallenge as a therapeutic option. We also provide an overview of published trials and trials in progress in this field, and outline the potential role of rechallenge in the current clinical setting.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Frontiers
dc.relation.ispartof Front Oncol. 2023 Feb 2;12:946850
dc.rights © 2023 Cremolini, Montagut, Ronga, Venturini, Yamaguchi, Stintzing and Sobrero. This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY) License (http://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3389/fonc.2022.946850
dc.subject.keyword Anti-EGFR
dc.subject.keyword Liquid biopsy
dc.subject.keyword Metastatic colorectal cancer (mCRC)
dc.subject.keyword Rechallenge
dc.subject.keyword Reintroduction
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking